New finger-pointing in Millargate
Peter Lewis, the former research director of British Biotech plc (LSE:BBG, BBIOY; Oxford U.K.), is going to be invited to submit evidence to the British Parliament's probe into the Millargate affair.
Ian Gibson, a member of the House of Commons' Science and Technology committee, revealed to BioCentury that the committee intends to invite Lewis to give his side of the story.
After some 11 weeks of Millargate, Lewis now has emerged as a key player in the affair (see BioCentury, May 20). In his testimony to the select committee last week, Andrew Millar, BBG's former director of clinical research, accused Lewis of "behaving treacherously" when he failed to pass on to BBG's board Millar's misgivings that the business plan and the evidence that the clinical trials of the company's compounds were out of kilter.
So far, Lewis has declined all approaches to give his version of events. If the select committee does invite him to give oral evidence, then he will be obliged to so. "We are going to ask him to submit written comments